All Exams Test series for 1 year @ ₹349 only
Question

What is the name of India's first indigenous CRISPR-based gene therapy for Sickle Cell Disease, launched in November 2025?

This question was previously asked in
RRB NTPC 2025 Under Graduate CBT 1 Question Paper PDF (20-Jun-2026) (Shift 3)
The correct answer is

BIRSA 101

India's first indigenous CRISPR-based gene therapy for Sickle Cell Disease is named BIRSA 101, launched in November 2025.

CRISPR gene-editing technology allows precise correction of the faulty gene responsible for Sickle Cell Disease, a hereditary blood disorder that distorts red blood cells into a sickle shape.

Developing this therapy indigenously marks a major step for India in advanced medical biotechnology and in tackling a disease common among tribal populations.

Hence, the therapy is named BIRSA 101.

Was this answer helpful?

Similar Questions

  1. In April 2025, BRIC-InStem in Bengaluru collaborated with which medical institution to successfully conduct India’s first gene therapy trial for Haemophilia?

  2. Which international health day was celebrated on November 14, 2025?

  3. What was the theme for World Leprosy Day 2025?

  4. Under an MoU signed on 2 September 2025 between the Department of Ex-Servicemen Welfare and Patanjali Yoggram, nearly six million veterans and their dependents will receive free access to which type of treatment?


Important Questions from Health

  1. Who led the team that explored innovative approaches to combat Alzheimer’s disease at the Bose Institute?

  2. Which parasitic disease has Niger officially eliminated as a public health threat?

  3. Which country has initiated the first-ever clinical trial for a vaccine targeting the Sudan species of the Ebola virus?

  4. Consider the following statements:

    Statement-I- Biolumpivaxin vaccine is expected to provide long-lasting immunity against all strains of the Lumpy Skin Disease virus.

    Statement-II- Vaccines typically stimulate the immune system to produce antibodies that can neutralize the specific pathogen they are designed to target

    Which one of the following is correct in respect to the above statements?

  5. Consider the following statements:

    Statement-I- Biolumpivaxin vaccine is expected to provide long-lasting immunity against all strains of the Lumpy Skin Disease virus.

    Statement-II- Vaccines typically stimulate the immune system to produce antibodies that can neutralize the specific pathogen they are designed to target

    Which one of the following is correct in respect to the above statements?

Need Expert Advice?
Upcoming Exams
RRB ALP
July 28, 2026
RRB Group D
August 03, 2026
Test Series
RRB NTPC img
Railways
RRB NTPC Under Graduate 2026 New Mock Test Series
1459 Tests 2 Tests Free
213 Attempts
4.3(512)
English, Hindi, Telugu +7 More

Start Your Preparation with Prepp Mobile App

Download the app from Google Play & App Store
Download the app from Google Play & App Store
Prepp Mobile App